Calypso Biotech BV
🇳🇱Netherlands
Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis
Phase 1
Completed
- Conditions
- Eosinophilic EsophagitisCeliac Disease
- Interventions
- Biological: PlaceboBiological: CALY-002
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Calypso Biotech BV
- Target Recruit Count
- 73
- Registration Number
- NCT04593251
- Locations
- 🇩🇪
Klinikum rechts der Isa der Technischen Universitaet Muenchen - Hospital, Munich, Germany
🇳🇴Alesund Hospital, Ålesund, Norway
🇧🇪UZ Leuven, Leuven, Belgium
© Copyright 2025. All Rights Reserved by MedPath